Cardiomyopathy – Novo Nordisk NN6019-4958

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of this study is to learn about the effectiveness of a study medication, called NNC6019-0001, at reducing deaths and illness related to the heart and blood circulation and to see how well it is tolerated. The study will also look at whether the study medication increases the ability to walk and quality of life.

To join the study, you or a loved one must:

• Be at least 18 years old
• Have been diagnosed with ATTR-CM, either hereditary (ATTRv) or wild-type (ATTRwt)
• Have protein buildup and thickening in your heart and HF symptoms
• Have been on a stable heart medication regimen (except for diuretics) for at least 4 weeks
• Be able to walk more than 50 meters (164 feet) during a 6-minute walk test
• Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.